MMR trivalent vaccine based on safety, reactogenicity and immunogenicity observed in 12-24 month-old healthy Filipino children: Evaluation of lot-to-lot consistency of a live-attenuated measles-mumps-rubella
- Author:
Salvacion Gatchalian
1
,
2
,
3
;
Margaret Lu-Fong
4
;
Leticia Cordero-Yap
5
;
Jossie Rogacion
6
;
Josefina Cadorna-Carlos
7
;
Htay Htay Han
3
;
Hans L Bock
3
Author Information
1. Research Institute for Tropical Medicine, Alabang, Muntinlupa, Philippines
2. Department of Pediatrics, College of Medicine, Philippines General Hospital, University of the Philippines, Manila, Philippines
3. GlaxoSmithKline Biologicals, Wavre, Belgium
4. Cardinal Santos Medical Center, Greenhills, San Juan, Metro Manila, Philippines
5. Holy Child Clinic, San Fernando, Pampanga, Philippines
6. Department of Pediatrics, St. Dominics Hospital, Bacoor, Cavite, Philippines
7. Department of Pediatrics, University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines
- Publication Type:Journal Article
- MeSH:
Human;
Male;
Female;
Infant;
MEASLES-MUMPS-RUBELLA VACCINE;
ENZYME-LINKED IMMUNOSORBENT ASSAY
- From:
Pediatric Infectious Disease Society of the Philippines Journal
2011;12(2):92-96
- CountryPhilippines
- Language:English
-
Abstract:
In this double-blind, randomized single-dose study, 194 healthy Filipino children aged 12-24 months were randomized into three groups (1:1:1) to receive one of the three lots of live-attenuated measles-mumps-rubella (MMR) vaccine to assess lot-to-lot consistency in safety and immunogenicity. Adverse events were recorded during 43-day post-vaccination follow-up period. Antibody levels were measured using ELISA pre-vaccination and on Day-60. No statistically significant differences were observed across groups for overall incidences of local and general symptoms (p>0.05) or immune response rates against the three antigens (p=0.835, 0.458 and 0.222 for anti-measles, anti-mumps and anti-rubella, respectively). The three lots demonstrated consistency in their reactogenicity and immunogenicity profile.
- Full text:2024080714101029978jo39_ja06.pdf
